Skip to main content

Table 3 Radicular and lumbar pain scores and Québec disability score during follow-up

From: Tumor necrosis factor-α blockade in recurrent and disabling chronic sciatica associated with post-operative peridural lumbar fibrosis: results of a double-blind, placebo randomized controlled study

Time points IFX group Placebo group All patients
n = 18 n = 17 n = 35
Radicular pain, VAS score (0–100 mm)
 Day 0 70.0 (65.0–85.0)* 55.0 (50.0–70.0) 70.0 (55.0–80.0)
 Day 0 post-injection 55.0 (28.0–70.0) 26.0 (15.0–40.0) 40.0 (18.0–60.0)
 Day 10 62.5 (40.0–80.0) 50.0 (40.0–63.0) 58.0 (40.0–75.0)
 Day 30 70.5 (60.0–80.0) 48.0 (32.0–60.0) 60.0 (40.0–75.0)
 Day 90 70.0 (60.0–80.0) 68.0 (50.0–72.0) 68.0 (52.0–78.0)
 Day 180 67.5 (45.0–80.0) 65.0 (30.0–73.0) 65.0 (35.0–80.0)
Lumbar pain, VAS score (0–100 mm)
 Day 0 60.0 (41.0–80.0) 50.0 (26.0–60.0) 55.0 (35.0–70.0)
 Day 0 post-injection 35.0 (0.0–60.0) 27.0 (5.0–42.0) 30.0 (0.0–60.0)
 Day 10 62.5 (34.0–70.0) 40.0 (35.0–70.0) 60.0 (34.0–70.0)
 Day 30 60.0 (35.0–70.0) 55.0 (30.0–69.0) 60.0 (30.0–70.0)
 Day 90 60.0 (30.0–78.0) 55.0 (45.0–60.0) 55.0 (40.0–70.0)
 Day 180 60.0 (35.0–70.0) 50.0 (30.0–70.0) 60.0 (32.0–70.0)
Québec disability score (0–100)
 Day 0 55.0 (37.0–68.0) 45.0 (31.0–62.0) 51.0 (37.0–65.0)
 Day 10 51.5 (39.0–66.0) 48.0 (39.0–55.0) 51.0 (39.0–59.0)
 Day 30 57.5 (38.0–67.0) 45.0 (33.0–55.0) 47.0 (34.0–66.0)
 Day 90 53.5 (38.0–69.0) 44.5 (36.0–53.5) 46.5 (38.0–64.0)
 Day 180 53.5 (37.0–70.0) 44.0 (34.0–51.0) 48.0 (34.0–60.0)
  1. Data are median (interquartile range)
  2. IFX Infliximab, VAS Visual analog scale
  3. *p<0.05 compared to placebo group